GDK Biotech released its performance for the first half of the year, with a net loss attributable to the parent company of 39.6531 million yuan
I'm PortAI, I can summarize articles.
According to the Zhitong Finance APP, GDK Biotech released its semi-annual report for 2025. During the reporting period, the company achieved operating revenue of 3.5242 million yuan, a year-on-year increase of 7.18%. The net loss attributable to shareholders of the listed company was 39.6531 million yuan, and the net loss attributable to shareholders of the listed company after deducting non-recurring gains and losses was 42.9408 million yuan, with a basic loss per share of 0.32 yuan
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments